Oct 27 2015
BIND Therapeutics, Inc., a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today announced that four abstracts have been accepted for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston, November 5-9, 2015.
The abstracts were published today on the AACR website at www.AACR.org.
"These posters highlight compelling data across multiple payloads and therapeutic pathways that reinforce what we believe is a powerful platform with the potential to create best-in-class therapeutics,” said Andrew Hirsch, president and chief executive officer at BIND. “These data add to a growing body of evidence that further validate the ability of our Accurins to control the biodistribution of therapeutic payloads to target diseased cells while limiting exposure to healthy tissues and minimizing on-target but off-tissue toxicities. We are committed to creating innovative medicines, both through internal discovery and collaborations with leading biopharmaceutical companies, that fully leverage the benefits of our proprietary nanomedicine platform."
The posters will include preclinical and clinical pharmacokinetic data from BIND’s clinical stage Accurin compound, BIND-014, data from BIND’s preclinical stage Accurin, BIND-510, and new data from a previously unannounced feasibility study with Merck, demonstrating the potential value of an Accurin formulation of Merck’s proprietary AKT inhibitor, MK-2206.
Poster presentations at AACR include the following:
BIND-014
1. Poster title: Cardiovascular safety profile of BIND-014 (docetaxel nanoparticles for injectable suspension) evaluated in phase 1 and 2 studies (Abstract/poster board #A161)
- Date/time: November 6, 2015; 12:15 – 3:15 pm ET
- Poster session category: Therapeutic Agents: Other
- Location: Poster Session A; Exhibit hall C-D
2. Poster title: Evaluation of total and encapsulated drug pharmacokinetics for BIND-014 (docetaxel nanoparticles for injectable suspension) in a phase 1 study (Abstract/poster board #B144)
- Date/time: November 7, 2015; 12:30 – 3:30 pm ET
- Poster session category: Pharmacokinetics and Pharmacodynamics
- Location: Poster Session B; Exhibit hall C-D
BIND-510
1. Poster Title: BIND-510 improves the pharmacokinetics, tolerability, tumor accumulation and tumor growth inhibition in preclinical models of cancer compared to vincristine sulfate (Abstract/poster board #C184)
- Date/time: November 8, 2015; 12:30 – 3:15 pm ET
- Poster session category: Therapeutic Agents: Other
- Location: Poster Session C; Exhibit Hall C-D
MK-2206 Accurin
1. Poster Title: Accurins improve the pharmacokinetics, pharmacodynamics, tolerability and anti-tumor activity of the AKT inhibitor MK-2206 (Abstract/poster board #C197)
- Collaborator: Merck
- Date/time: November 8, 2015; 12:30 – 3:30 pm ET
- Poster session category: Therapeutic Agents: Small Molecule Kinase Inhibitors
- Location: Poster Session C
Source: http://www.bindtherapeutics.com/